Four insights:
1. Mr. Rigby brings more than 28 years of experience in the pharmaceutical, biopharmaceutical, medical device and drug delivery industries to CollPlant.
2. Previously, Mr. Rigby was president and CEO of SteadyMed, a specialty pharmaceutical company that United Therapeutics bought in August 2018.
3. Along with his new role at CollPlant, Mr. Rigby will continue to serve as president and CEO of SteadyMed, a United Therapeutics corporation.
4. CollPlant focuses on 3D bioprinting of tissues and organs, medical aesthetics and the development and commercialization of tissue repair products for orthobiologics.
More articles on biologics:
Ortho RTi releases results of 2 regenerative medicine studies
California neuroscience institute joins regenerative medicine clinical trial: 5 notes
ThermoGenesis makes orthopedic partnership: 3 notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
